Premium
Immunohistochemical study of the epithelial‐to‐mesenchymal transition phenotype in nonsmall cell lung cancer
Author(s) -
RodriguezLopez Xavier Luis,
PerezMorales Jaileene,
SantiagoCardona Pedro
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.804.53
Subject(s) - lung cancer , epithelial–mesenchymal transition , adenocarcinoma , medicine , metastasis , cancer , tissue microarray , immunohistochemistry , pathology , cancer research , oncology
Lung cancer is the leading cause of cancer death in both men and women in the United States. Lung cancer is divided into non‐small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for 80% of all primary lung cancers and subdivided into adenocarcinoma (ADC), squamous cell carcinoma (SCC), and large cell carcinoma (LCC). Due to late diagnosis, only 16% of diagnosed patients live beyond 5 years, but this survival rate increases if the cancer has not yet metastasized. Recent developments in lung cancer therapies depend on precise histological subtyping of NSCLC. Accurate discrimination of SCC from the remaining NSCLCs is crucial for understanding the outcome and metastatic dissemination of lung cancer. The epithelial‐to‐mesenchymal transition (EMT) has been associated with an early proclivity for metastasis in lung cancer. We want to identify if N‐cadherin and E‐cadherin expression in tumor samples can be of clinical value for discriminating between SCC and ADC and in predicting the development of lung cancer metastasis. We performed immunohistochemistry analysis in two tissue microarrays that contained 24 lung cancer patients. An EMT phenotype was defined as a low expression of E‐cadherin and high expression of N‐cadherin. An EMT phenotype was observed in 58% cases of SCC and carried prognostic utility for lymph node metastasis. The EMT phenotype observed in SCC can be suggested as potential markers of malignant transformation. Support or Funding Information R25GM096955, 2R25GM082406, 2U54CA163071‐06 This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .